Maze Loses Nearly a Third of Market Share on Mixed Midstage Kidney Drug Data

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data in Maze Therapeutics’ trial, according to Mizuho.